NBIX vs SYK: fair value comparison
Neurocrine Biosciences, Inc. and Stryker Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, NBIX currently sits closer to the top of our discount ranking. SYK carries the stronger quality grade.
| NBIX | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $166.23 | $303.13 |
| 12-month range | $131.78–$167.77 | $294.73–$387.02 |
| Sector rank | #18 of 113 Healthcare | #21 of 113 Healthcare |
| Quality grade | C+ | A |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: NBIX fair value analysis · SYK fair value analysis